Teva Pharmaceutical Industries Limited (TEVA) Expected to Post Quarterly Sales of $5.85 Billion

Brokerages expect that Teva Pharmaceutical Industries Limited (NYSE:TEVA) will report $5.85 billion in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Teva Pharmaceutical Industries Limited’s earnings. The lowest sales estimate is $5.76 billion and the highest is $6.12 billion. Teva Pharmaceutical Industries Limited reported sales of $5.04 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 16.1%. The firm is expected to announce its next quarterly earnings report before the market opens on Thursday, August 3rd.

On average, analysts expect that Teva Pharmaceutical Industries Limited will report full year sales of $5.85 billion for the current year, with estimates ranging from $22.80 billion to $24.10 billion. For the next fiscal year, analysts expect that the firm will post sales of $22.93 billion per share, with estimates ranging from $22.27 billion to $23.80 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Teva Pharmaceutical Industries Limited.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.06. The firm had revenue of $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.20 earnings per share.

Several equities research analysts recently weighed in on TEVA shares. Vetr cut shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $31.94 target price for the company. in a research note on Monday, May 22nd. Jefferies Group LLC reiterated a “hold” rating and issued a $33.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, June 23rd. CIBC reiterated a “buy” rating and issued a $43.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Friday, April 7th. Oppenheimer Holdings, Inc. set a $43.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research note on Thursday, April 6th. Finally, Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, April 17th. Fifteen equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $42.88.

A number of hedge funds have recently added to or reduced their stakes in TEVA. Cribstone Capital Management LLC raised its stake in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares in the last quarter. Kistler Tiffany Companies LLC raised its stake in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares in the last quarter. FNY Managed Accounts LLC acquired a new stake in Teva Pharmaceutical Industries Limited during the first quarter worth approximately $123,000. Finally, Sterling Investment Advisors Ltd. raised its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares in the last quarter. 56.20% of the stock is owned by hedge funds and other institutional investors.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 0.96% during mid-day trading on Friday, reaching $31.86. The company had a trading volume of 6,223,163 shares. The company’s 50-day moving average price is $32.01 and its 200-day moving average price is $32.29. Teva Pharmaceutical Industries Limited has a 52-week low of $27.59 and a 52-week high of $55.79. The company has a market capitalization of $32.34 billion, a PE ratio of 6.20 and a beta of 0.46.

TRADEMARK VIOLATION WARNING: This piece was reported by Rincon Hill News and is the property of of Rincon Hill News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://rinconhillneighbors.org/2017/08/19/teva-pharmaceutical-industries-limited-teva-expected-to-post-quarterly-sales-of-5-85-billion-updated-updated.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries Limited (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.